Amplia Therapeutics Ltd. ATX

Eli Lilly (NYSE: LLY) announced new global collaborations focused on ion channel drug discovery with OmniAb and a trial partnership with Amplia Therapeutics in KRAS G12C-mutant lung cancer. The OmniAb agreement centers on applying its ion channel platform to Eli Lilly's neuroscience research pipeline. The Amplia collaboration targets a clinical trial program that combines FAK and KRAS G12C-directed therapies for lung cancer patients. These deals expand Eli Lilly's external R&D partnerships...

Eli Lilly (NYSE: LLY) reported that its KRAS G12C inhibitor olomorasib received FDA Breakthrough Therapy designation for advanced pancreatic cancer in patients with a KRAS G12C mutation. The company entered a new clinical trial collaboration with Amplia Therapeutics to test olomorasib in combination with Amplia's FAK inhibitor narmafotinib in advanced non small cell lung cancer. These developments highlight Eli Lilly's efforts to broaden its oncology portfolio beyond its diabetes and obesity...

HIGHLIGHTS Amplia has executed a Clinical Trial Collaboration & Supply Agreement (CTCSA) with Eli Lilly & Company, to evaluate the Company’s investigational FAK inhibitor narmafotinib in combination with Lilly’s late‑stage investigational next generation KRAS inhibitor olomorasibThe collaboration is underpinned by narmafotinib’s growing base of clinical evidence and a strong scientific rationale that FAK activation is a key driver of resistance to KRAS G12C inhibitorsThe collaboration further ex

Amplia Therapeutics Ltd (ASX:ATX, OTCQB:INNMF) has signed a clinical collaboration agreement with Eli Lilly and Company to evaluate its lead drug narmafotinib alongside Lilly’s next-generation KRAS G12C inhibitor olomorasib in patients with advanced non-small cell lung cancer (NSCLC). The...

HIGHLIGHTS A manuscript describing comprehensive preclinical studies of narmafotinib in models of pancreatic cancer is now available online.The findings provide further evidence of narmafotinib's ability to target several important drivers of pancreatic cancer progression, including fibrosis, chemotherapy resistance and metastatic spread. Melbourne, Australia, July 31, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), announces that a scien

HIGHLIGHTS New patent application published covering chemically novel FAK inhibitors discovered by AmpliaApplication expands Amplia’s intellectual property portfolio supporting its FAK inhibitor programIf granted, patent protection for the new molecules and their use would extend to 2046New compounds broaden pipeline optionality and may support future development and partnering opportunities Melbourne, Australia, July 09, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF

Melbourne, Australia, July 07, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX, OTCQB:INNMF), (“Amplia” or the “Company”), is pleased to announce the appointment of Mr Brett Carter to the Board of Directors as non-executive director, effective from 6 July 2026. Amplia Board chair Ms Jane Bell AM commented, “I am delighted to welcome Brett to the Board at this exciting time in the Company’s development. His extensive experience in the structuring and negotiation of licensing, acquis

Melbourne, Australia, July 06, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX, OTCQB:INNMF), (“Amplia” or the “Company”), announces Board changes further to a Board renewal and succession plan. Dr Warwick Tong will retire as Board Chairman on 30 June 2026 and remain as a Non-Executive Director (NED) of the Company. Dr Tong has been a Director of Amplia since 4 May 2018 following the acquisition of Amplia Therapeutics Pty Ltd in April 2018. He was elected Chairman of the Board in A

Melbourne, Australia, June 22, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX | OTCQB:INNMF), (“Amplia” or the “Company”) provides a letter to shareholders from CEO and Managing Director Dr. Chris Burns outlining the potential for the Company’s best-in-class FAK inhibitor narmafotinib in combination with the emerging KRAS inhibitor class following exciting new data presented at the American Society of Clinical Oncology Annual Meeting earlier this month: Dear Fellow Shareholders, T

HIGHLIGHTS New Phase 2b study builds on compelling Phase 1b/2a ACCENT study data to lay foundation for Phase 3 registrational studyFocus on investigating new, daily dosing of narmafotinib in combination with standard regimen of gemcitabine and Abraxane in patients with advanced pancreatic cancerAccelerated initiation made possible by clinic-ready drug product and resources transitioned from AMPLICITY studyPatient enrolment planned to begin by Q4 2026 Melbourne, Australia, May 19, 2026 (GLOBE NEW

We can readily understand why investors are attracted to unprofitable companies. By way of example, Amplia Therapeutics...

HIGHLIGHTS Mature data from Amplia’s ACCENT trial in pancreatic cancer is being presented at the prestigious American Association of Cancer Research (AACR) annual meetingThe ACCENT trial investigates the combination of narmafotinib with standard-of-care chemotherapyThe data presented includes additional analysis of the promising efficacy and survival data reported last month Melbourne, Australia, April 22, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics limited (ASX:ATX | OTCQB:INNMF), (“Amplia” or

NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are now available for on-demand viewing. The forum featured CEO chats and company presentations from leadership teams representing innovative companies across the biotechnology, medical device, and pharmaceutical sectors, offering investors insights into emerging tec